Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne
Immunobiological features of the dendritic cells (DC) were studied for the production of DC-vaccine (DCV) optimization. DC were differentiated in vitro in GM-CSF (previously studied concentration 72 ng/ml and IL-4 0–45 ng/ml containing medium. GM-CSF compounds by Pharmsynthez (Russia) and Cell Genix...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/131 |
| _version_ | 1797875938716811264 |
|---|---|
| author | T. L. Nehaeva |
| author_facet | T. L. Nehaeva |
| author_sort | T. L. Nehaeva |
| collection | DOAJ |
| description | Immunobiological features of the dendritic cells (DC) were studied for the production of DC-vaccine (DCV) optimization. DC were differentiated in vitro in GM-CSF (previously studied concentration 72 ng/ml and IL-4 0–45 ng/ml containing medium. GM-CSF compounds by Pharmsynthez (Russia) and Cell Genix (Germany) and IL-4 by Cell Genix (Germany) were used. Comparative assays of mature and immature DC immunophenotype using different GM-CSF compounds was performed. CD1а, CD83, CD86, CD80, CCR7 и HLA DR are recommended optimal markers of DC for the standardization of technologic process. Flow cytometry and immunocytochemistry assays revealed no differences in mature DC markers expression (p>0,05). This indicates the expediency of Pharmsynthez (Russia) GM-CSF usage for DCV production. Optimal IL-4 concentrations (5–15 ng/ml) providing qualitative characteristics for DCV production were found using second level one-way polynomial model. |
| first_indexed | 2024-04-10T01:54:20Z |
| format | Article |
| id | doaj.art-8017ec4b98174332bc22e721726f2404 |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:54:20Z |
| publishDate | 2016-02-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-8017ec4b98174332bc22e721726f24042023-03-13T09:05:47ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-02-01035256131Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant NeT. L. Nehaeva0ФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-ПетербургImmunobiological features of the dendritic cells (DC) were studied for the production of DC-vaccine (DCV) optimization. DC were differentiated in vitro in GM-CSF (previously studied concentration 72 ng/ml and IL-4 0–45 ng/ml containing medium. GM-CSF compounds by Pharmsynthez (Russia) and Cell Genix (Germany) and IL-4 by Cell Genix (Germany) were used. Comparative assays of mature and immature DC immunophenotype using different GM-CSF compounds was performed. CD1а, CD83, CD86, CD80, CCR7 и HLA DR are recommended optimal markers of DC for the standardization of technologic process. Flow cytometry and immunocytochemistry assays revealed no differences in mature DC markers expression (p>0,05). This indicates the expediency of Pharmsynthez (Russia) GM-CSF usage for DCV production. Optimal IL-4 concentrations (5–15 ng/ml) providing qualitative characteristics for DCV production were found using second level one-way polynomial model.https://www.siboncoj.ru/jour/article/view/131иммунотерапиядендритные клеткивакцинаоптимизация |
| spellingShingle | T. L. Nehaeva Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne Сибирский онкологический журнал иммунотерапия дендритные клетки вакцина оптимизация |
| title | Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne |
| title_full | Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne |
| title_fullStr | Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne |
| title_full_unstemmed | Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne |
| title_short | Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne |
| title_sort | autologous dendritic cell vaccine optimization for therapy of patients with disseminated malignant ne |
| topic | иммунотерапия дендритные клетки вакцина оптимизация |
| url | https://www.siboncoj.ru/jour/article/view/131 |
| work_keys_str_mv | AT tlnehaeva autologousdendriticcellvaccineoptimizationfortherapyofpatientswithdisseminatedmalignantne |